Passive antiamyloid immunotherapy for Alzheimer's disease

Registro completo de metadados
MetadadosDescriçãoIdioma
Autor(es): dc.contributorUniversidade de São Paulo (USP)-
Autor(es): dc.contributorUniversidade Estadual Paulista (Unesp)-
Autor(es): dc.contributorUniversity of Texas Health Science Center at Houston (UTHealth)-
Autor(es): dc.contributorSanta Casa Bh Ensino e Pesquisa-
Autor(es): dc.contributorUniversidade Federal de Minas Gerais (UFMG)-
Autor(es): dc.creatorLoureiro, Júlia C.-
Autor(es): dc.creatorPais, Marcos V.-
Autor(es): dc.creatorStella, Florindo [UNESP]-
Autor(es): dc.creatorRadanovic, Marcia-
Autor(es): dc.creatorTeixeira, Antônio Lúcio-
Autor(es): dc.creatorForlenza, Orestes V.-
Autor(es): dc.creatorDe Souza, Leonardo Cruz-
Data de aceite: dc.date.accessioned2022-02-22T00:32:37Z-
Data de disponibilização: dc.date.available2022-02-22T00:32:37Z-
Data de envio: dc.date.issued2020-12-11-
Data de envio: dc.date.issued2020-12-11-
Data de envio: dc.date.issued2020-05-01-
Fonte completa do material: dc.identifierhttp://dx.doi.org/10.1097/YCO.0000000000000587-
Fonte completa do material: dc.identifierhttp://hdl.handle.net/11449/201113-
Fonte: dc.identifier.urihttp://educapes.capes.gov.br/handle/11449/201113-
Descrição: dc.descriptionPurpose of reviewAntiamyloid therapy of Alzheimer's disease tackles the overproduction and clearance of the amyloid-beta peptide (Aβ). Immunotherapeutic compounds were tested in large-scale trials. We revisit the recent literature focusing on randomized-controlled trials (RCT) using monoclonal anti-Aβ antibodies.Recent findingsForty-three articles on anti-Aβ passive immunotherapy for Alzheimer's disease were published between January 2016 and October 2019 regarding 17 RCTs: 13 phase III trials using the monoclonal antibodies bapineuzumab, solanezumab, gantenerumab, crenezumab, and aducanumab; three phase II with crenezumab and aducanumab; and one phase I trial with BAN2401. Studies resulted largely negative considering the effect of the treatment on primary and secondary outcome variables. The incidence of the most important adverse effect, amyloid-related imaging abnormalities (ARIAs) ranged between 0.2 and 22%, in treatment groups. Primary endpoints were not met in eight trials, and five trials were discontinued prior to completion.SummaryPassive immunotherapy RCTs failed to show clinically relevant effects in patients with clinically manifest or prodromal dementia. The high incidence of ARIAs indicates that the risk of adverse events may outweigh the benefits of these interventions. Ongoing studies must determine the benefit of such interventions in preclinical Alzheimer's disease, addressing the effect of antiamyloid immunotherapy in samples of asymptomatic carriers of autosomal-dominant mutations related to early-onset Alzheimer's disease.-
Descrição: dc.descriptionLaboratório de Neurociências LIM-27 Departamento e Instituto de Psiquiatria Hospital das Clinicas Hcfmusp Faculdade de Medicina Universidade de São Paulo-
Descrição: dc.descriptionInstituto de Biociências Universidade Estadual Paulista (UNESP)-
Descrição: dc.descriptionDepartment of Psychiatry and Behavioral Sciences McGovern Medical School University of Texas Health Science Center at Houston (UTHealth)-
Descrição: dc.descriptionSanta Casa Bh Ensino e Pesquisa-
Descrição: dc.descriptionPrograma de Pós-Graduação em Neurociências Universidade Federal de Minas Gerais (UFMG)-
Descrição: dc.descriptionDepartamento de Clínica Médica Faculdade de Medicina Ufmg-
Descrição: dc.descriptionInstituto de Biociências Universidade Estadual Paulista (UNESP)-
Formato: dc.format284-291-
Idioma: dc.languageen-
Relação: dc.relationCurrent Opinion in Psychiatry-
???dc.source???: dc.sourceScopus-
Palavras-chave: dc.subjectAducanumab-
Palavras-chave: dc.subjectAlzheimer's disease-
Palavras-chave: dc.subjectCrenezumab-
Palavras-chave: dc.subjectGantenerumab-
Palavras-chave: dc.subjectMonoclonal antibody-
Palavras-chave: dc.subjectPassive immunotherapy-
Palavras-chave: dc.subjectSolanezumab-
Título: dc.titlePassive antiamyloid immunotherapy for Alzheimer's disease-
Aparece nas coleções:Repositório Institucional - Unesp

Não existem arquivos associados a este item.